aTyr Pharma (NASDAQ:LIFE) Issues Earnings Results, Beats Estimates By $0.01 EPS

aTyr Pharma (NASDAQ:LIFE) issued its quarterly earnings data on Thursday. The biotechnology company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.01, Yahoo Finance reports. The company had revenue of $0.24 million during the quarter, compared to analysts’ expectations of $0.11 million.

aTyr Pharma Price Performance

NASDAQ LIFE traded up $0.01 during trading hours on Friday, reaching $1.61. 258,232 shares of the stock traded hands, compared to its average volume of 367,840. The stock has a 50 day simple moving average of $1.77 and a two-hundred day simple moving average of $1.55. aTyr Pharma has a 1 year low of $1.08 and a 1 year high of $2.70. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.27 and a quick ratio of 6.27. The company has a market cap of $109.38 million, a price-to-earnings ratio of -1.79 and a beta of 1.27.

Analyst Ratings Changes

LIFE has been the subject of several analyst reports. HC Wainwright reissued a “buy” rating and issued a $35.00 price objective on shares of aTyr Pharma in a research note on Friday. Royal Bank of Canada reduced their target price on aTyr Pharma from $19.00 to $16.00 and set an “outperform” rating for the company in a report on Friday, March 15th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $23.67.

About aTyr Pharma

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.